Technology evaluation: ABT-510, Abbott.
SourceCurrent Opinion in Molecular Therapeutics, 6, 4, (2004), pp. 451-457
Article / Letter to editor
Display more detailsDisplay less details
Current Opinion in Molecular Therapeutics
SubjectEBP 2: Effective Hospital Care; UMCN 1.3: Tumor microenvironment; UMCN 5.2: Endocrinology and reproduction
ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.